Cargando…

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer

Leptin is a peptide hormone, mainly known for its role as a mediator of adipose tissue endocrine functions, such as appetite control and energy homeostasis. In addition, leptin signaling is involved in several physiological processes as modulation of innate and adaptive immune responses and regulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buonaiuto, Roberto, Napolitano, Fabiana, Parola, Sara, De Placido, Pietro, Forestieri, Valeria, Pecoraro, Giovanna, Servetto, Alberto, Formisano, Luigi, Formisano, Pietro, Giuliano, Mario, Arpino, Grazia, De Placido, Sabino, De Angelis, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599120/ https://www.ncbi.nlm.nih.gov/pubmed/36291602 http://dx.doi.org/10.3390/biom12101394

Ejemplares similares

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
por: Santaniello, Antonio, et al.
Publicado: (2019)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
por: Napolitano, Fabiana, et al.
Publicado: (2019)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
por: Servetto, Alberto, et al.
Publicado: (2021)

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
por: Buonaiuto, Roberto, et al.
Publicado: (2023)

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
por: Gargiulo, Piera, et al.
Publicado: (2016)

Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
por: Pietroluongo, Erica, et al.
Publicado: (2023)

Immunological signature of patients with thymic epithelial tumors and Good syndrome
por: Malfitano, Anna Maria, et al.
Publicado: (2022)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
por: De Placido, Pietro, et al.
Publicado: (2022)

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
por: Foschini, Francesca, et al.
Publicado: (2020)

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2020)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Prevalence of Sarcopenia in Women with Breast Cancer
por: Morlino, Delia, et al.
Publicado: (2022)

Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie
por: De Angelis, Carmine, et al.
Publicado: (2021)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA
por: Ottaviano, Margaret, et al.
Publicado: (2021)

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature
por: Pensabene, Matilde, et al.
Publicado: (2018)

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2017)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023)

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
por: Caltavituro, Aldo, et al.
Publicado: (2023)

Tumor characteristics and prognosis in familial breast cancer
por: Arpino, G., et al.
Publicado: (2016)

Extraskeletal Ewing’s sarcoma of the mediastinum: Case report
por: Caltavituro, Aldo, et al.
Publicado: (2023)

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
por: Rosa, Roberta, et al.
Publicado: (2013)

Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response
por: Cernera, Gustavo, et al.
Publicado: (2023)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a
por: Barone, Ines, et al.
Publicado: (2023)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
por: Di Mauro, Concetta, et al.
Publicado: (2017)

Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes
por: Servetto, Alberto, et al.
Publicado: (2023)

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer
por: Giordano, Cinzia, et al.
Publicado: (2023)

Correction: Lobular intraepithelial neoplasia arising within breast fibroadenoma
por: Limite, Gennaro, et al.
Publicado: (2014)

c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
por: Belli, Stefania, et al.
Publicado: (2020)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
por: De Placido, S, et al.
Publicado: (2017)

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
por: Formisano, Luigi, et al.
Publicado: (2015)

How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy
por: Della Corte, Luigi, et al.
Publicado: (2023)

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uu5k7t2mr8gv13i8a4j7g78khj